Deglycosylated Ricin A Chain-Conjugated Anti-CD19
Adult B Acute Lymphoblastic Leukemia
Albert Einstein College of MedicinePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Adult B Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE SWOG Cancer Research Network | Phase 3 | BBB |
PEGASPARGASE National Cancer Institute (NCI) | Phase 3 | BBB |
DEXAMETHASONE Mayo Clinic | Phase 3 | BBB |
Cyclophosphamide The First Affiliated Hospital of Soochow University | Phase 3 | BBB |
METHOTREXATE Massachusetts General Hospital | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Deglycosylated Ricin A Chain-Conjugated Anti-CD19 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →